2019 Archived Content
OVERVIEW | DOWNLOAD BROCHURE | KEYNOTES | SPEAKER BIOGRAPHIES | BREAKOUT DISCUSSIONS | SHORT COURSES | TRAINING SEMINARS | SPEAKER LIST | ATTENDEES

The 18th Annual World Preclinical Congress is a key scientific and networking event yielding new partnerships that accelerate preclinical research and translation across all therapeutic areas. It offers a unique opportunity for leading scientists and executives from industry and academia as well as technology providers to come together and exchange expertise and opinions in the areas of disease modeling, drug metabolism and toxicity, target ID and validation, preclinical immuno-oncology, translational CNS research and more. The Congress will be taking place as part of Cambridge Healthtech Institute’s World Pharma Week: the premier meeting place for pharmaceutical decision makers!

Conference Programs

June 17

▶ Extracellular Vesicles

June 18-19

▶ 3D Cellular Models

▶ Preclinical Strategies, Models & Tools in Oncology (Shared Conference with IO Pharma Congress)

▶ Chemical Biology and Target Validation

▶ CNS Targets and Translational Strategies

▶ Optimizing Drug Metabolism & Pharmacokinetics

▶ Introductory Immunology for Cancer and Autoimmune Drug Discovery

June 19-20

▶ iPS Cells for Disease Modeling and Drug Discovery

▶ Patient-Derived Tumor Organoids (Shared Conference with IO Pharma Congress)

▶ Target Identification & Phenotypic Screening

▶ Blood-Brain Barrier

▶ Predicting Drug Toxicity

▶ Small Molecules for Immuno-Oncology Therapeutics (Shared Conference with IO Pharma Congress)

▶ Cancer Immunotherapy Models (Shared Conference with IO Pharma Congress)

▶ Applying 3D Models

▶ Practical Introduction to PKPD Modeling in Drug Discovery and Development: Better, Faster, Cheaper

Featured Speakers

Emma Lees, PhD,

Emma Lees, PhD,
Vice President and Oncology Site Head, Bristol-Myers Squibb

Chad May, PhD,

Chad May, PhD,
Senior Vice President, Research and Development, Maverick Therapeutics

Juliet Williams, PhD,

Juliet Williams, PhD,
Executive Director, Oncology Drug Discovery, Novartis

Johan Luthman, PhD, SVP,

Johan Luthman, PhD, SVP,
Neuroscience Clinical Development, Neurology Business Group, Eisai, Inc.

Christoph Patsch, PhD,

Christoph Patsch, PhD,
Team Lead Stem Cell Assays, Disease Relevant Cell Models and Assays, Chemical Biology, Therapeutic Modalities, Roche

Gabriele Proetzel, PhD,

Gabriele Proetzel, PhD,
Director, Regenerative Medicine, Takeda Pharmaceuticals, Inc

Gary Gintant, PhD,

Gary Gintant, PhD,
Senior Research Fellow, AbbVie

Holly D. Soares, PhD,

Holly D. Soares, PhD,
Head, Translational Neuroscience, AbbVie

Nicholas Brandon, PhD,

Nicholas Brandon, PhD,
Chief Scientist, Neuroscience, IMED, AstraZeneca

Urban_Laszlo

Laszlo Urban, MD, PhD,
Global Head, Preclinical Secondary Pharmacology, Novartis Institutes for Biomedical Research (NIBR)

Jason Ekert, PhD,

Jason Ekert, PhD,
Head, Complex in vitro Models, R&D Platform Technology & Science, GlaxoSmithKline

Raghu Kalluri, MD, PhD,

Raghu Kalluri, MD, PhD,
Professor and Chair, Department of Cancer Biology, University of Texas MD Anderson Cancer Center